PARP Inhibitor Biomarkers Market By Product
PARP Inhibitor Biomarkers Market By Services
PARP Inhibitor Biomarkers Market By Application
PARP Inhibitor Biomarkers Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global PARP Inhibitor Biomarkers Market Snapshot
Chapter 4. Global PARP Inhibitor Biomarkers Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Product Estimates & Trend Analysis
5.1. by Product & Market Share, 2019 & 2031
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Product:
5.2.1. Kits
5.2.2. Assays
Chapter 6. Market Segmentation 2: by Services Estimates & Trend Analysis
6.1. by Services & Market Share, 2019 & 2031
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Services:
6.2.1. BRCA 1&2 Testing
6.2.2. HRD Testing
Chapter 7. Market Segmentation 3: by Application Estimates & Trend Analysis
7.1. by Application & Market Share, 2019 & 2031
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Application:
7.2.1. Breast Cancer
7.2.2. Ovarian Cancer
7.2.3. Others
Chapter 8. PARP Inhibitor Biomarkers Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Product, 2019-2031
8.1.2. North America PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Services, 2019-2031
8.1.3. North America PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031
8.1.4. North America PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
8.2. Europe
8.2.1. Europe PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Product, 2019-2031
8.2.2. Europe PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Services, 2019-2031
8.2.3. Europe PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031
8.2.4. Europe PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
8.3. Asia Pacific
8.3.1. Asia Pacific PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Product, 2019-2031
8.3.2. Asia Pacific PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Services, 2019-2031
8.3.3. Asia-Pacific PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031
8.3.4. Asia Pacific PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
8.4. Latin America
8.4.1. Latin America PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Product, 2019-2031
8.4.2. Latin America PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Services, 2019-2031
8.4.3. Latin America PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031
8.4.4. Latin America PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
8.5. Middle East & Africa
8.5.1. Middle East & Africa PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Product, 2019-2031
8.5.2. Middle East & Africa PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Services, 2019-2031
8.5.3. Middle East & Africa PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031
8.5.4. Middle East & Africa PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Myriad Genetics, Inc.
9.2.2. Ambry Genetics
9.2.3. Thermo Fisher Scientific, Inc.
9.2.4. Illumina, Inc.
9.2.5. CENTOGENE N.V.
9.2.6. Amoy Diagnostics Co., Ltd.
9.2.7. Invitae Corporation
9.2.8. NeoGenomics Laboratories.
9.2.9. QIAGEN
9.2.10. Agilent Technologies, Inc.
9.2.11. Other Prominent Players
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.